Overview of Mycocort

Mycocort: Definition and Classification as a Combination Medicine

Property	Description
Active Ingredients	Hydrocortisone, Miconazole Nitrate
Form	Topical Cream (Fixed-Dose Combination)
Pharmacological Class	Corticosteroid and Azole Antifungal
General Purpose	Simultaneous inflammation and fungal control
Origin	Synthetic Derivatives

Mycocort is a highly specialized, dual-action, fixed-dose combination (FDC) topical preparation designed for direct application to the skin (cutaneous administration). This medicine is classified as a combination of a corticosteroid and an azole antifungal, a unique grouping within dermatological agents. The product is clinically recognized for its utility in managing inflammatory skin conditions complicated by microbial involvement, distinguishing it from single-agent formulations. It is typically available as a prescription-only (Rx) treatment, reflecting its potent combination of active ingredients.

What are the Active Ingredients in Mycocort?

The active ingredients in Mycocort are Hydrocortisone and Miconazole Nitrate, each serving a critical and separate therapeutic function. Hydrocortisone is a mild-potency steroid belonging to the glucocorticoid class, and its primary purpose is to provide an anti-inflammatory effect. Topical glucocorticoids provide relief from skin irritation and inflammation. This means the medicine works quickly to relieve unpleasant symptoms like swelling and redness. The second ingredient, Miconazole Nitrate, is a synthetic imidazole derivative that acts as a broad-spectrum antifungal.

What is the General Purpose of Mycocort?

The general purpose of Mycocort is to deliver a dual-action therapeutic approach that provides rapid relief from inflammation while simultaneously controlling the underlying fungal infection. This combination is specifically formulated to address skin conditions where inflammation and irritation—such as itching, swelling, and redness—are present alongside a susceptible fungal or yeast overgrowth. As an azole antifungal, this component is used to stop the growth of fungi and yeasts responsible for skin infections. This indicates the medicine is designed not just to soothe symptoms but to eliminate the cause. The medication’s core benefit is its ability to immediately soothe the distressed skin while the Miconazole Nitrate component works to eliminate the microbial cause, promoting more effective resolution.

Regulatory References

NLM Glucocorticoid Study

What side effects are possible with Mycocort?

Possible Side Effects and Safety Information

The safety profile for Mycocort (Hydrocortisone/Miconazole Nitrate topical cream) is primarily defined by local reactions and the potential, albeit rare, for systemic effects associated with its corticosteroid component, as outlined in official regulatory documents.

Documented Adverse Reactions

Adverse reactions are classified by regulatory agencies based on frequency:

Uncommon (ge 1/1,000 to <1/100): These typically involve local reactions at the application site, such as skin irritation, skin burning sensation, pruritus (itching), and urticaria (hives).
Frequency Not Known: Post-marketing reports have included cases of hypersensitivity (allergic reactions), contact dermatitis, and rare systemic effects.

These effects are generally classified under Skin and Subcutaneous Tissue Disorders, though systemic absorption can potentially involve Endocrine Disorders.

Systemic and Special Population Safety

The most serious documented safety consideration relates to the absorption of the corticosteroid component. Topical corticosteroids can be absorbed in amounts sufficient to cause systemic effects, including HPA axis suppression (adrenal suppression) and Cushing’s syndrome, though these are rare.

Special Population Risk: Regulatory agencies note that the pediatric population is at a greater risk of systemic effects due to a higher surface area-to-weight ratio. Use in infants should avoid long-term continuous therapy.

Safety-Related Restrictions: Official labeling includes several constraints. The cream must not be used ophthalmically (in the eyes). Furthermore, components of the cream may damage latex, so contact with latex products (such as contraceptive diaphragms or condoms) must be avoided.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Guidance

This section describes the officially documented manifestations of overdose and the required actions as outlined in government regulatory information for topical creams containing hydrocortisone and miconazole nitrate.

Documented Overdose Risks and Manifestations

Domain	Official Regulatory Information
Topical Overuse	Prolonged and excessive topical use can result in local skin irritation.
Systemic Risk	The hydrocortisone component can be absorbed, potentially causing systemic corticosteroid effects, including adrenocortical suppression and, in rare instances, signs consistent with Cushing's syndrome.
Population Risk	Infants and children are noted to be at greater risk of systemic absorption due to their higher skin surface area to body weight ratio.

Required Emergency Actions

Accidental Oral Ingestion

If the cream is accidentally swallowed, patients are explicitly instructed to contact a doctor or go to the nearest hospital casualty department straight away for medical care. Symptoms following ingestion may include nausea, vomiting, or diarrhea.

Topical Overdose Management

In cases of overdose resulting from excessive topical application, the primary action required is the discontinuation of therapy. Treatment is generally symptomatic and supportive. If systemic effects occur, management involves the gradual reduction of the amount used and periodic evaluation for HPA-axis suppression.

Therapeutic Uses of Mycocort

What Mycocort Treats: Main Uses and Benefits

Mycocort is commonly used across conditions presenting with acute episodes and is considered relevant for easing symptoms related to inflammatory or irritative states. It is applied across domains where additional symptomatic support is needed, assisting with the management of dual-pathology skin conditions.

This type of combination medicine is utilized for the topical treatment of inflamed dermatoses where infection by susceptible organisms and inflammation co-exist.

Mycocort is generally used to help with conditions such as candidal intertrigo, athlete's foot (Tinea pedis), and ringworm (Tinea corporis), particularly when symptoms related to inflammatory or irritative states are present. It supports symptom management in clinical settings marked by temporary physiological imbalance. This application helps address symptom clusters that may become intense or disruptive, and contributes to improved comfort during periods of heightened symptoms.

Alleviating Acute Itching and Sensory Discomfort

Mycocort is applied across domains where additional symptomatic support is needed, and is relevant for managing symptoms that interfere with daily comfort, such as itching (pruritus), redness, and swelling. It is used during phases when symptoms become more noticeable and may help patients cope more steadily with difficult episodes. This provides support that helps ease the overall symptom burden.

Quick Fact: Relief for Dual Symptoms The product is commonly used when symptoms cluster into patterns requiring supportive management of both the fungal skin condition and associated inflammation.

Regulatory References

HPRA Summary of Product Characteristics

Eligibility and Restrictions for Use

Who can and cannot use Mycocort?

Regulatory documents define specific populations who are permitted, restricted, or prohibited from using Mycocort (Hydrocortisone/Miconazole Nitrate topical cream).

Contraindicated Populations (Absolute Non-Eligibility)

Mycocort use is contraindicated in patients with known hypersensitivity to the active ingredients (Hydrocortisone or Miconazole Nitrate). It must not be used for specific skin conditions, including rosacea, acne vulgaris, perioral dermatitis, or primary skin infections caused by viruses (e.g., Herpes simplex) or bacteria.

Age and Physiological Restrictions

Population	Regulatory Status
Adults	Permitted for use.
Children < 10 Years	Should not be used unless prescribed by a doctor.
Infants	Contraindicated with occlusive dressings (e.g., baby napkins).
Pregnancy	Avoid use unless considered essential by a physician; treatment of large surfaces is not recommended.
Lactation	Caution is recommended; application to the breast area is not advised.

Eligibility is further restricted for all populations when using latex contraceptives (e.g., condoms) due to potential damage from the cream constituents.

What should I know about interactions with other medicines?

Mycocort's official interaction profile primarily stems from its Miconazole Nitrate component, which is classified in regulatory documents as a potent inhibitor of Cytochrome P450 isoenzymes CYP3A4 and CYP2C9. These pharmacokinetic interactions carry official constraints on the co-administration of specific medicinal products that are metabolized by these pathways. The Hydrocortisone component's metabolism may also be decreased by Miconazole, potentially resulting in higher local serum concentrations.

A key pharmacodynamic interaction is documented with oral anticoagulants, such as warfarin. Co-administration can officially enhance the anticoagulant effect, requiring close monitoring of coagulation parameters, such as the International Normalized Ratio (INR). Furthermore, due to the inhibitory effect on CYP3A4, certain co-administered drugs known to prolong the QT interval may be officially contraindicated.

A critical physical incompatibility restriction is officially documented regarding the product's use with certain medical devices. Mycocort must not be used concurrently with latex condoms or diaphragms, as the cream is known to cause physical damage to the latex material, which compromises integrity.

Regulatory information notes that the risk of systemic interaction is officially increased in infants and young children and when the cream is applied under occlusive dressings (including baby napkins), as these conditions increase the potential for systemic absorption.

Mechanism of Action

The mechanism of Mycocort involves the coordinated action of two distinct pharmacodynamic effects: modulation of the host's inflammatory signaling and inhibition of fungal cell growth and viability.

Modulating Inflammation via Glucocorticoid Receptor Activation

This mechanism involves the corticosteroid component, hydrocortisone, acting as an agonist for the cytoplasmic Glucocorticoid Receptor (GR). By activating the GR, the drug initiates transrepression, a molecular process that suppresses the production of key proteins and enzymes, such as Phospholipase A2 ( PLA2). The resulting physiological effect is the reduction of the Arachidonic Acid Cascade, which lowers the local synthesis of potent inflammatory mediators. This cascade leads to localized vasoconstriction and a decrease in tissue edema and erythema.

Destabilizing Fungal Cell Integrity

The antifungal component, miconazole nitrate, engages a distinct mechanism by acting as a powerful inhibitor of the fungal enzyme 14-alpha-demethylase ( CYP51). This inhibition blocks the essential conversion of lanosterol to ergosterol, the primary structural sterol of the fungal cell membrane. The physiological consequence of this blockage is the accumulation of toxic sterol precursors and the destruction of the cell membrane's structural integrity, which leads to a reduction in fungal cell viability via structural and functional destabilization.

Dosage and Administration Information

How to Use Mycocort: Official Administration Guidelines

Mycocort, the combination cream containing miconazole nitrate (2% w/w) and hydrocortisone (1% w/w), is administered exclusively via the topical route for external cutaneous use only. It is not approved for ophthalmic, oral, or intravenous administration.

Application and Dosing Schedule

Official prescribing information outlines a precise application and duration schedule for this combination medicine. The cream should be applied as a thin layer to the affected skin area and gently rubbed in until it is absorbed. Application is typically scheduled once or twice daily, depending on regional guidelines. Prior to application, the affected area should be gently cleansed and thoroughly dried.

Usage Constraint	Official Instruction
Application Route	External topical use only.
Frequency	Once or twice daily.
Maximum Duration	Generally limited to 7 days of continuous use.

Treatment Pattern and Duration

The combination product is intended specifically for the initial stages of treatment when inflammatory symptoms are most noticeable. The use of the hydrocortisone-containing combination cream is for a short-term, limited duration, often with a maximum of seven continuous days. Once the inflammatory symptoms have subsided, treatment is typically continued using a single-agent antifungal cream or powder (e.g., miconazole alone) to ensure complete clearance of the fungal infection, often continuing for a total treatment duration of two to five weeks.

Population-Specific Use

Specific caution and medical supervision are required when using the cream in infants and children. Due to the systemic absorption risk, application to large surface areas or under occlusive dressings, which includes the diaper/nappy area, should be avoided. Hands must be washed thoroughly after application, unless they are the area being treated.

Recent Clinical Evidence

Research evidence / Overview of studies for Mycocort

Evidence for use in Inflammatory Superficial Skin Infections

The research examining Mycocort in conditions such as tinea (like athlete’s foot or ringworm) and candidal intertrigo primarily consists of studies that were designed to observe responses in groups using the combination cream and groups using the individual ingredients—miconazole alone or hydrocortisone alone. These trials were designed to observe short-term symptom patterns in adult patients with these inflammatory conditions. Researchers focused on outcomes linked to inflammatory or irritative states, as well as outcomes describing episodic or acute changes.

Studies monitored how symptoms evolved in the observed populations, and findings describe patterns related to the skin's appearance and the presence of fungal growth. The research examined measurements of microbiological status and clinical status over defined time intervals.

While studies contribute to understanding short-term changes, the evidence is limited regarding how these findings translate over longer periods. There is limited information for long-term outcomes or recurrence rates after the study treatment concluded.

Evidence for use in Seborrhoeic Dermatitis

Research examined multiple outcomes related to physical discomfort in adult patients experiencing Seborrhoeic Dermatitis of the Scalp, a condition characterized by fluctuating or episodic manifestations. The studies explored various outcomes linked to inflammatory states, including changes in the visible condition of the scalp and the presence of the Malassezia pathogen.

The controlled studies monitored responses over defined time intervals during clinical status assessments, changes in pathogen count, and to describe patterns of recurrence during the follow-up period. Findings describe patterns observed in these studies regarding the evolution of these measured outcomes during and immediately after the treatment course.

The research so far describes that the data are still emerging, and certainty remains low regarding the clinical status assessment for body areas other than the scalp. The current evidence is narrowly focused, and data for seborrhoeic dermatitis presenting in other locations are limited.

Long-term Studies and Follow-up Durations

The available research primarily focuses on short-term symptom patterns during the initial treatment course. Studies were conducted during defined time intervals, meaning the observation periods used in the clinical trials were limited in duration. The durability of the observed responses over extended time is an area where data are still emerging.

Evidence in Special Populations

The initial clinical research was largely conducted on adult patients diagnosed with the studied conditions. The results apply only to the populations studied.

While specific research has examined the responses in certain adult subgroups, only a limited number of trials included the pediatric population. Therefore, limited data are available for certain groups, particularly infants and children. There is also limited information regarding outcomes in older adults or individuals with certain other health conditions.

What is Still Uncertain About Mycocort Evidence

Research helps show what has been observed so far, but there are several areas where the evidence remains limited and further research is ongoing.

The certainty remains low regarding long-term effects, as follow-up durations were limited across the main studies. Data for assessing clinical status in complex, highly recurrent, or chronic forms of the conditions are limited. Additionally, comparative evidence against other existing treatments is not fully established in some research areas. Findings describe group patterns, not personal outcomes, and research provides context but not individual predictions.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Mycocort (FAQ)

Q: What is the main difference between Mycocort and other similar over-the-counter creams?

Mycocort is a specialized, prescription-only (Rx) combination medicine that contains two active ingredients: a mild steroid (hydrocortisone) and an antifungal (miconazole). This dual-action formulation is what distinguishes it from many single-agent over-the-counter products. Regulatory documents state that Mycocort is reserved for the initial short-term treatment of inflammatory skin conditions complicated by microbial growth.

Q: What should I do if I accidentally miss applying Mycocort?

Official guidance on administration suggests avoiding applying a double amount to make up for a missed application. If the missed dose is remembered soon after, it may be applied. However, if it is nearly time for the next scheduled dose, official guidance specifies that the missed dose should be skipped entirely and the regular schedule continued.

Q: Can Mycocort be used on sensitive skin areas, like the face?

Official prescribing information indicates that the medicine is not for application to the face. This restriction is in place because use on the face can increase the risk of systemic absorption of the corticosteroid component. Furthermore, Mycocort is officially contraindicated for specific facial conditions like rosacea and perioral dermatitis.

Q: Is there a generic version of Mycocort available?

The active ingredients in Mycocort are miconazole and hydrocortisone, which are widely available in other generic combination products. However, the regulatory status of a therapeutically equivalent generic product for the specific Mycocort brand name must be confirmed by consulting authoritative drug databases maintained by agencies like the FDA. These resources list drugs approved as interchangeable generics.

Q: Does Mycocort interact with common vitamins or supplements?

Official product information describes that a healthcare provider should be informed about all drugs being used, including over-the-counter medicines, natural products, and vitamins. The potential for interactions exists even with supplements, and the Miconazole component, in particular, is noted in regulatory documents for its interaction with certain enzyme pathways.

Q: What is the risk of skin thinning associated with Mycocort?

As Mycocort contains a topical corticosteroid (hydrocortisone), official safety information indicates there is a documented risk of causing thinning (atrophy) of the skin. This risk is typically associated with prolonged use or when the cream is applied to the face or under occlusive dressings. This is one reason why regulatory documents specify short-term use for this product.

Q: What official body approved Mycocort, and when?

The antifungal component, miconazole, was first granted FDA approval as a topical cream in January 1974. For the specific fixed-dose combination product (Mycocort), the official approval date and authorizing body can be verified by consulting the specific regulatory body's public drug database (e.g., Drugs@FDA in the US).

Q: Are there any reported cases of Mycocort causing hair loss?

Official regulatory documents list specific side effects reported in clinical trials and post-marketing surveillance in the Adverse Reactions sections of the drug label. If a symptom like hair loss is not listed there, it means it was not reported at a statistically significant frequency to be officially documented as a common or uncommon side effect.

Q: What are the signs that Mycocort might not be working for a condition?

According to authoritative health resources, if the symptoms or underlying skin problem do not show signs of improvement or if they become worse after the expected initial treatment period, this may indicate the medicine is not working. Additionally, if new irritation such as burning, stinging, or an unexpected rash develops, official guidance specifies that this status should be communicated to a healthcare provider.

Q: Can Mycocort cause discoloration or changes to skin pigmentation?

The corticosteroid component, hydrocortisone, is associated in health literature with possible effects like the appearance of reddish-purple lines or thinning of the skin. However, specific documentation for hypopigmentation (skin lightening) or hyperpigmentation (skin darkening) is not universally listed in the provided official adverse reaction profiles.

Q: What is the typical shelf life of a tube of Mycocort?

All medications have an expiration date stamped on the tube or box by the manufacturer. This date is the final date for which the manufacturer guarantees the product’s full stability and potency. Official labeling may also indicate the period of time the cream remains stable and effective after the tube is first opened.

Q: Is it okay to use Mycocort past the expiration date?

Official guidance describes that unused or expired drugs should be disposed of properly. Outdated medicine should be thrown away, as the manufacturer cannot guarantee the potency or stability of the ingredients past the printed expiration date.

Q: Is it true that Mycocort can affect my blood sugar levels?

Regulatory documentation suggests that topical hydrocortisone may potentially affect blood sugar. It is noted that topical hydrocortisone can cause or worsen conditions like hyperglycemia (high blood sugar) in rare systemic cases. Patients who have diabetes or glucose intolerance are advised in official prescribing information that they may need to be monitored more closely during therapy.

Q: Can I apply makeup or moisturizer over Mycocort?

Official labeling for the topical hydrocortisone component generally indicates that cosmetics or other skin care products should not be used on the treated areas. This precaution helps prevent increased systemic absorption of the medicine, unless a healthcare provider specifically instructs otherwise.

Q: What should I do if I get a rash while using Mycocort?

Official information states that if signs of a reaction develop—including a skin rash, burning, stinging, swelling, or irritation—the medicine's use is often discontinued. If these symptoms persist or if signs of a hypersensitivity (allergic) reaction develop, official sources advise that this status should be communicated to a healthcare provider immediately.

Q: Can Mycocort be used on broken or scraped skin?

Official warnings indicate that Mycocort should not be applied to cuts, scrapes, or damaged skin. This restriction is noted in regulatory information because applying the cream to large sores or areas where the skin is broken may increase the chance of the medicine being absorbed systemically, which could lead to adverse effects.

How should Mycocort be stored and disposed of?

How to Store and Dispose of Mycocort

Official regulatory documents define specific requirements for how Mycocort must be stored and handled to maintain its stability and effectiveness.

Storage Conditions

Requirement	Official Statement
Temperature	Store below 30 C.
Protection	Protect from light and moisture.
Handling	Keep the tube tightly closed.

Mycocort must be stored in a manner that protects it from environmental factors that could degrade the product. Regulatory information specifies that the medicine should be kept below 30 C and shielded from both light and moisture. To prevent exposure, the container must remain tightly closed when not in use.

Regarding disposal, official documentation states there are no special requirements for disposal of Mycocort. Unused medicine may generally be discarded following common household trash disposal guidelines, unless otherwise directed by local regulations.

Mycocort